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In the 1990s, chemotherapy has been shown able to improve
survival of patients presenting with advanced non-small cell lung
cancer (NSCLC, 1995). The survival benefit was obtained with
first-generation active cytostatic agents – mainly ifosfamide,
vinblastine, vindesine, mitomycin (MMC) – in combination with
cisplatin (Donnadieu et al, 1991). New active drugs – the second
generation – have appeared during the last decade, including
gemcitabine, paclitaxel, docetaxel, vinorelbine and irinotecan.
Their role in addition or in place of the first-generation agents,
which should not be considered as obsolete for the unique reason
that they are older and less fashionable, has yet to be defined
(Meert et al, 1999). 
In this context, we have performed a systemic review of the
literature about the role of one of the first-generation drugs, mito-
mycin (MMC), in the management of NSCLC. In order to deter-
mine if it is worthy to further conduct trials with that agent, we
have searched answers to the 3 following questions: (1) is MMC
an active drug against NSCLC? (2) does MMC improve the results
when added to other active agents? (3) is MMC useful for salvage
therapy? We have performed this investigation by using a method-
ology similar to that we have already used to conduct evidence-
based medicine analyses of the literature. 
MATERIAL AND METHODS 
To be eligible for the systematic review, a trial had to fulfil the
following criteria: to deal only with NSCLC, to have been
published as a full paper in the English or French language, to
have a prospective design and to assess the effect of MMC in a
randomized trial or in a first-line or second-line phase II trial
according to the studied question. 
Trials were identified by an electronic search (Medline) in addi-
tion to the use of the personal bibliography of one of the authors
and by consulting the references reported in the selected articles. 
Each trial was read and assessed for methodology by 12 investi-
gators, including 11 physicians and 1 biostatistician. Each investi-
gator independently extracted the data from the articles and
disagreements were resolved by consensus. Randomized trials
were evaluated for methodology by 2 quality scores calculated on
the basis of the data reported in the publications: the score
proposed by Chalmers et al (1981) and used by Marino in two
meta-analyses (Marino et al, 1994, 1995); and the score proposed
by the ELCWP (European Lung Cancer Working Party) (Mascaux
et al, 2000). Phase II trials were assessed by the ELCWP score for
phase II studies (Meert et al, 1999). 
The result of a phase III trial was considered as conclusive if the
P value for the statistical test comparing the survival distributions
between arms for the overall patients populations was <0.05 in
favour of the experimental arm. The trial was then called ‘posi-
tive’. In the other situations (statistically significant survival
benefit for the control arm or non-statistically significant differ-
ence in survival distributions), it was called ‘negative’. 
The association between the quality scores or between a quality
score treated as continuous variable and another continuous vari-
able was measured by the Spearman ranks correlation coefficient.
Its significance was assessed by testing a null hypothesis of
equality to zero of this coefficient. The comparison between
quality scores according to the value of a discrete variable was
made by non-parametric Mann–Whitney (for dichotomic vari-
ables) or Kruskal–Wallis (for nominal variables with multiple
classes) tests. To compare regimens according to the drug dose-
intensity, we used the theoretical dose-intensity for the drug
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(reported in mg/m2/week) by dividing the theoretical absolute dose
administered by the theoretical duration of the treatment before
response evaluation (if not reported, we made the calculations with
3 cycles of treatment). 
Confidence intervals (CI) for the response rate to the chemo-
therapy regimen were, for consistency, recalculated using the
exact binomial distribution. 
For objective response, the numbers of eligible and assessable
patients were recorded in each article as described by the authors. 
For the quantitative aggregation of the antitumoral response
results and the reported toxic deaths, we measured the treatment
effects using the odds ratios calculated on the contingency tables
observed in each trials. The individual odds ratios were combined
using the Peto method after having tested the homogeneity of the
odds ratios estimated in each study. 
For the quantitative aggregation of the survival results reported
in the randomised phase III trials, we measured the treatment
effect by the hazard ratio (HR) between the survival distributions.
For each trial, this HR was estimated by a method depending on
the results provided in the publications. The most accurate method
consisted to calculate the estimated HR and its standard error
using 2 of the following parameters: the HR point estimate, the
log-rank statistic or its P value, the O-E statistic (difference
between numbers of observed and expected events) or its variance.
If not available, we looked for the total number of events and the
log-rank statistic or its P value allowing calculation of an approxi-
mation of the HR estimate. Finally, if it was impossible to apply
the second method, we extracted from the graphical representation
of the survival distributions survival rates at some specified times
chosen on a trial by trial basis in order to reconstruct the log-rank
statistic and its variance. The individual HR point estimates were
combined after acceptation of the null hypothesis of the homo-
geneity of the treatment effect across the various trials, using the
Peto method in order to obtain a global HR estimate of the treat-
ment effect. By convention, a HR < 1 implied a survival benefit for
the experimental arm. 
All reported P values are two-tailed. 
RESULTS 
A total of 19 trials were found to be eligible for the present 
systematic review: 5 phase II trials assessing MMC as first-line
single-agent therapy, 10 phase III randomized trials assessing the
addition of MMC to a basic active regimen and 4 phase II trials
assessing the role of MMC-containing regimens as second-line
chemotherapy for advanced NSCLC. 
Question 1: is MMC an active drug against NSCLC? 
5 studies (Israel et al, 1975; Samson et al, 1978; Ruckdeschel et al,
1981; Niell et al, 1989; Veeder et al, 1992a) including 202 assess-
able patients provided results about the activity of MMC when
given as first-line single-agent therapy. Their design is phase II for
3 and randomized phase III for 2. 3 specifically deal with squa-
mous cell carcinoma and one with adenocarcinoma and large cell
carcinoma. Their main characteristics and results are shown in
Table 1. 
The global quality score ranged between 26.1% and 81.9% with
a median of 57.3%. There was a good correlation between the
score and the year of publication (r = 1) while no significant corre-
lation was found with the number of eligible patients (r = 0.6; 
P = 0.55). 
The reported response rates ranged from 19 to 50%, with an
overall response rate of 25% (95% Cl: 19–32%). 
Question 2: does MMC improve the results when added
to other active agents? 
10 randomized trials comparing a basic chemotherapy regimen 
with or without MMC (Einhorn et al, 1986; Crino et al, 1988, 
1990; Bonomi et al, 1989, Luedke et al, 1990; Fukuoka et al, 1991;
Shinkai et al, 1991; Weick et al, 1991; Mylonakis et al, 1992;
Gandara et al, 1993; Masutani et al, 1996) were available for a meta-
analysis. Their main characteristics and results are summarized in
Table 2 8 of them included more than 2 arms but we considered only
the 2 arms of interest, leading to a total of 1769 eligible patients, 876
treated in the experimental arm with MMC and 893 in the control
arm without MMC. As shown in Table 2, most often the data 
were missing to consider the number of randomized patients for 
the aggregation. The basic chemotherapy regimen was cisplatin–
vindesine in 4 trials, cisplatin–vinblastine in 3 and cisplatin–
etoposide, cisplatin or vindesine in 1 each. In 7 trials, a reduction of
the dosage of at least one of the basic drugs was performed in the
MMC arm. Significant improvement of response rate was reported
in 3 trials but none was associated with significant survival improve-
ment. All the trials were thus considered as negative. 
The quality scores of the randomized trials are reported in Table
3. The ELCWP score ranged from 52.8% to 86.8% with a median
of 66.5% and the Chalmers one from 30.6% to 64.8% with a
median of 43.5%. There was a significant correlation between
both scales (r = 0.68; P = 0.03). We found no significant correla-
tion between the scores and the number of eligible patients
included into the study, the date of study activation or the date of
publication. 
Table 1 Characteristics and results of the studies assessing the role of MMC as first-line single-agent therapy 
Reference n assessable  MMC DI (mg/m2/wk) OR (%) 95% Cl (%) ELCWP IV (%) ELCWP EV (%) ELCWP QS (%) 
patients
Israel et al, 1975 20 0.02 mg/kg 10 (50%) 26% – 74% 22.2 28.9 26.1 
Samson et al, 1978 37 2.78 7 (20%) 5% – 33% 50 36.5 42 
Ruckdeschel et al, 1981 28 6.67 5 (19%) 2% – 34% 50 61.7 57.3 
Niell et al, 1989 53 2.5 10 (19%) 7% – 30% 69.4 70.7 70.2 
Veeder et al, 1992b 64 2.78 19 (30%) 18% – 42% 83.3 81 81.9 
Overall 202  51 (25.2%) 19% – 32% 
MMC: mitomycin C, DI: dose-intensity (mg/m2/wk), OR: objective response; IV: internal validity; EV: external validity; QS: quality score. 1152 JP Sculier et al 
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No significant bias being found in quality scores between the
trials, a meta-analysis of survival and response results was
performed. 
For survival, the individual HR were calculated by one of the
methods reported in the Material and methods section. In one case,
the HR was estimated using the total number of events and the log-
rank statistic, in 7 using extracted survival rates from the graphical
representations of the survival distributions and in 2 using the
global number of events in each arm. We aggregated firstly all the
trials and secondly a subgroup of the 3 trials that respected 
the same drug dosage in the 2 arms. These meta-analyses failed to
show a significant difference between the regimens with or
without MMC. The individual and pooled hazard ratios (HR) are
shown in Figures 1 and 2. The aggregation of the 10 randomized
trials resulted in an overall HR of 0.95 (95% confidence interval or
CI: 0.83–1.10) while the pooled HR for the 3 trials subgroup was
1.05 (95% CI: 0.83–1.33). The test for heterogeneity of the treat-
ment effect was not significant (P = 0.93). 
For response, the analysis had to deal with heterogeneity of the
effect of the addition of MMC mainly due to the study of Luedke
et al (1990) who compared vindesine with or without MMC. 
As shown in Figures 3 and 4, when this study is included, a signif-
icant odds-ratio (OR) was obtained in favour of MMC-containing
regimens: 1.48 (95% CI 1.17–1.86); when it is excluded, the OR
(test for heterogeneity: P = 0.54) is not anymore significantly 
associated with an improved response rate: 1.21 (95% CI 0.95–
1.54). 
The number of observed toxic deaths was not significantly
different between the arms with or without MMC, with an 
OR of 1.55 (95% CI: 0.73–3.28; P = 0.98; test for heterogeneity: 
P = 0.53). 
Table 2 Characteristics and reported results of the randomized studies assessing the role of the addition of MMC to a basic regimen 
Reference Basic  
n eligible patients chemotherapy
(n randomized) regimen OR rate (%) MS time (wks)
MMC arm Control arm  MMC arm Control arm P MMC arm Control arm P
Einhorn et al, 1986 41 (?) 41 (?) CDDP-VDS* 20 27 NS 17 26 NS 
Crino et al, 1990 57 (?) 69 (?) CDDP-VP16  26 30 NS 37 35 NS 
Bonomi et al, 1989 176 (?) 175 (?) CDDP-VBL* 20 13 S 23 25 NS 
Luedke et al, 1990 143 (?) 141 (?) VDS* 27 <1 S 20 15 NS 
Fukuoka et al, 1991 68 (69) 67 (68) CDDP-VDS* 43 33 NS 42 50 NS 
Shinkai et al, 1991 61 (62) 63 (64) CDDP-VDS* 35 23 NS 45 39 NS 
Weick et al, 1991 134 (139) 142 (156) CDDP-VBL* 24 17 NS 25 21 NS 
Mylonakis et al, 1992 51 (51) 52 (52) CDDP-VBL 18 31 NS 32 35 NS 
Gandam et al, 1993 110 (?) 108 (?) CDDP  27 14 S 54 40 NS 
Masutani et al, 1996 35 (?) 35 (?) CDDP-VDS* 43 29 NS 33 36 NS 
OR: objective response; MS: median survival; S: significant; NS: non significant; CDDP: cisplatin; VDS: vindesine; VBL: vinblastine; * = with reduction of the
dosage of the basic drugs in the MMC-experimental arm. 
Einhorn, 1986
Crino, 1988-90
Bonomi, 1990
Luedke, 1990
Fukuoka, 1991
Shinkai, 1991
Weick, 1991
Mylonakis, 1992
Gandara, 1993
Masutani, 1996
OVERALL
0.0 0.5 1.0 1.5 2.0
Figure 1 Results of the survival meta-analysis of the 10 randomized trials
comparing a chemotherapy regimen with or without MMC
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Mylonakis, 1992
Gandara, 1993
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Figure 2 Results of the survival meta-analysis of the subgroup of 3 trials
comparing a chemotherapy regimen with or without MMC, without drug
dosage reduction 
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Figure 3 Results of the objective response rate meta-analysis of the 10
randomized trials comparing a chemotherapy regimen with or without MMC Mitomycin in non-small cell lung cancer treatment 1153
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Question 3: is MMC useful for salvage therapy? 
On the 4 prospective phase II trials found in the literature (Table
4), 3 deal with a combination of MMC with vindesine (Kris et al,
1985; Sculier et al, 1986, Bonomi et al, 1989) and 1 with cisplatin
and vinblastine (Gridelli et al, 1992). The ELCWP quality score
for phase II trials ranged from 21.1% to 75% with a median of
61.1%. The response rate ranged for the MMC–vindesine regimen
from 0% to 17%, with an overall response rate of 10.5% (95% 
CI: 1.7–19.4%). It was 6% for the cisplatin–vinblastine–MMC
combination. 
DISCUSSION 
Our systematic review intended to answer 3 questions about the
role of mitomycin in the management of advanced NSCLC. A
response to 2 of them is possible: MMC is an active drug for this
disease as shown by the phase II trials testing its activity as single-
agent first-line chemotherapy and the meta-analysis of the random-
ized trials fails to obtain any survival advantage when MMC is
added to a basic combination regimen with first-generation cyto-
static agents (mainly cisplatin and/or vinca alcaloids). For the last
question concerning the role of the drug for salvage chemotherapy,
the response is less evident because of the limited number of
published studies on the topic. 
To perform our systematic review, we have used a methodology
that was similar to prior studies of this type reported by our Group.
The principle is to assess the trial quality by methodological scales
– the Chalmers and ELCWP scores – in order to search for poten-
tial methodological aspects of the published trials that might
explain heterogeneity of the reported treatment effects. If there is
no significant difference among the publications, as in the present
report, we go further in our analysis and perform a quantitative
aggregation (meta-analysis) of the results of the individual trials.
This approach applied to MMC in advanced NSCLC was rela-
tively easy because all the trials provide similar results. All the
phase II studies assessing the role of MMC as first-line single-
agent therapy revealed that the drug is active and none of the
randomized studies assessing the role of the addition of MMC to a
basic regimen showed a survival advantage for the experimental
arm. We had thus not to compare for quality ‘positive’ and ‘nega-
tive’ studies. The only significant finding was an improved quality
in favour of more recently published phase II trials, which can be
very well explained by the amelioration of the trials methodology
obtained over the 3 last decades. 
Mitomycin is associated with a 25% objective response rate
when administered as single-agent first-line chemotherapy in
advanced NSCLC. Most of the authors consider that the cut-off to
consider a drug as active in this disease is defined by the observa-
tion of response rates above 15 to 20%. The results reported by the
5 trials described in Table 1 are consistent, despite being
conducted over a relatively long period (~25 years). Some of them
were performed with some specific histological subtypes of
NSCLC but we do not believe that this heterogeneity is a potential
source of bias. The meta-analysis that we performed about
response in NSCLC failed to show significantly different effects
according to the histological type. 
The next step of the systematic review was to identify the poten-
tial benefit for the patient of the inclusion of MMC in the
chemotherapy treatment. The primary endpoint that we choose
was survival, the endpoint usually used by the investigators for
phase III randomized trials. Other endpoints that could be of
interest for the patients are symptom control, quality of life or toxi-
city of the treatment but the publications reported no data or too
poorly described data to allow a meaningful aggregation. The
main problem in the interpretation of the results of our meta-
analysis is, in 7 of the 10 randomized trials, a dosage reduction of
the non-MMC drugs in the experimental arm compared to control
arm. For this reason, as shown in Figures 1 and 2, we performed
two meta-analyses, one with all the studies and another with the 3
studies with the purest design to address our question. None
revealed a survival advantage for MMC-regimens but due to
the small number of adequately designed randomized trials
Table 3 Quality scores of the randomized studies assessing the role of the addition of MMC to a basic regimen 
Reference Chalmers score % ELCWP score % 
Internal validity External validity Total  Protocol design Performance analysis Total 
Einhorn, 1986 50 18 40.9 61.9 50 54.8 
Crino, 1988/90 28.6 36 30.6 66.7  66.1 66.4 
Bonomi, 1990 38.1 12 30.6 50 54.8 52.9 
Luedke, 1990 38.1 30 35.8 52.4 53.1 52.8 
Fukuoka, 1991 57.1 48 54.6 90.5  71.9 79.3 
Shinkai, 1991 71.4 48 64.8 85.7  87.5 86.8 
Weick, 1991 47.6 42 46 61.9 73.4 68.9 
Mylonakis, 1992 47.6 48 47.7 73.8  53.1 61.3 
Gandara, 1993 47.6 48 47.7 59.5  71.7 66.7 
Masutani, 1996 38.1 42 39.2 61.9  74.2 69.2
Einhorn, 1986
Crino, 1988-90
Bonomi, 1990
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Shinkai, 1991
Weick, 1991
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Figure 4 Results of the objective response rate meta-analysis of the
randomized trials after exclusion of the study by Luedke et al (1990)1154 JP Sculier et al 
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(only 3), the provided evidence might not be sufficient to change 
practice. 
Although of less interest, we aggregated also the response rates.
We had to deal in the analysis with a heterogeneity problem
because of the trial of Luedke et al (1990) who reported in a very
large trial a very significantly improved response rate when MMC
was added to vindesine but without significant effect on survival.
This trial may be criticized because the response rate obtained for
vindesine was very low and is thus not in agreement with the
majority of the other studies published with this drug in the litera-
ture. When this trial is omitted for meta-analysis (Figure 4), there
is no response rate improvement by the addition of MMC while
when it is included (Figure 3), there is a positive advantage in
favour of MMC-containing chemotherapy. 
The last point that we analysed was the role of MMC in salvage
chemotherapy regimens (Table 4). In fact, the only regimen that
has been the topic of publications is MMC–vindesine. The
response rate reported is around 10%, which is rather marginal. In
fact, we believe that the available literature for this question has to
be considered as non-conclusive because of a lack of sufficient
data, including about first-line chemotherapy characteristics. 
In conclusion, the present systematic review shows that MMC is
an active drug against advanced NSCLC but does not improve
survival when added to other first-generation active cytostatic
agents like cisplatin, vindesine and vinblastine. It should not be
anymore used in this indication. Nevertheless its role for salvage
chemotherapy or in combination with the second-generation active
drugs require to be studied in further investigations. 
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